Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

  1. Benito-Villalvilla, C.
  2. de la Rocha-Muñoz, A.
  3. López-Abente, J.
  4. Eggel, A.
  5. Bottoli, I.
  6. Severin, T.
  7. Woisetschläger, M.
  8. Palomares, O.
Revue:
Allergy: European Journal of Allergy and Clinical Immunology

ISSN: 1398-9995,  0105-4538

Année de publication: 2023

Volumen: 78

Número: 4

Pages: 1060-1072

Type: Article

DOI: 10.1111/ALL.15567 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus